Status:
COMPLETED
Eptinezumab in Healthy Japanese Subjects
Lead Sponsor:
H. Lundbeck A/S
Conditions:
Healthy
Eligibility:
All Genders
20-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to investigate how eptinezumab enters, moves through and exits the body. Safety and tolerability will also be investigated.
Detailed Description
The study will consist of 18 healthy Japanese subjects, divided into two single dose cohorts with 9 subjects in each cohort.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Healthy Japanese subjects with a BMI of ≥ 18.5 and ≤ 25 kg/m2
- Other in- and exclusion criteria may apply
Exclusion
Key Trial Info
Start Date :
April 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 13 2020
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT04336449
Start Date
April 1 2020
End Date
August 13 2020
Last Update
August 14 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
P-One Clinic
Tokyo, Japan